Anastrozole-Induced Dermatitis: Report of a Woman with an Anastrozole-Associated Dermatosis and a Review of Aromatase Inhibitor-Related Cutaneous Adverse Events

Kim, Yoo Jung; Cohen, Philip R.

doi:10.1007/s13555-020-00353-3

Cited by 11 publications

(4 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Pregnancy represents the etiologic cause in 2–6% of patients [ 6 , 19 , 45 ]. Oral contraceptive pills and aromatase inhibitors are associated with EN development [ 47 , 48 ].…”

Section: Etiologymentioning

confidence: 99%

Erythema Nodosum: A Practical Approach and Diagnostic Algorithm

et al. 2021

View full text Add to dashboard Cite

Erythema nodosum is the most common form of panniculitis and is characterized by tender erythematous nodules mainly in the lower limbs on the pretibial area. The exact cause of erythema nodosum is unknown, although it appears to be a hypersensitivity response to a variety of antigenic stimuli. Although the etiology is mostly idiopathic, ruling out an underlying disease is imperative before diagnosing primary erythema nodosum. Erythema nodosum can be the first sign of a systemic disease that is triggered by a large group of processes, such as infections, inflammatory diseases, neoplasia, and/or drugs. The most common identifiable causes are streptococcal infections, primary tuberculosis, sarcoidosis, Behçet disease, inflammatory bowel disease, drugs, and pregnancy. We propose a diagnostic algorithm to optimize the initial work-up, hence initiating prompt and accurate management of the underlying disease. The algorithm includes an initial assessment of core symptoms, diagnostic work-up, differential diagnosis, and recommended therapies. Several treatment options for the erythema nodosum lesions have been previously reported; nevertheless, these options treat the symptoms, but not the triggering cause. Making an accurate diagnosis will allow the physician to treat the underlying cause and determine an optimal therapeutic strategy.

show abstract

“…Pregnancy represents the etiologic cause in 2–6% of patients [ 6 , 19 , 45 ]. Oral contraceptive pills and aromatase inhibitors are associated with EN development [ 47 , 48 ].…”

Section: Etiologymentioning

confidence: 99%

Erythema Nodosum: A Practical Approach and Diagnostic Algorithm

et al. 2021

View full text Add to dashboard Cite

show abstract

“…A PubMed search of the literature using the terms "erythema nodosum" and "breast cancer" identified a case report describing the development of EN in breast cancer patients treated with aromatase inhibitors (AIs) [ 19 , 20 ]. Although the etiology of EN in these patients was not identified, the skin rash disappeared rapidly after AI discontinuation.…”

Section: Discussionmentioning

confidence: 99%

Development of Erythema Nodosum After Olaparib Treatment in a Patient With Recurrent Breast Cancer and BRCA2 Mutation: A Case Report

Saito,

Fujii,

Banno

et al. 2023

Cureus

View full text Add to dashboard Cite

BRCA1 and 2 mutations are known to be associated with breast cancer, and olaparib, a poly (adenosine diphosphate-ribose) polymerase (PARP) inhibitor, has been shown to be effective in cells carrying these mutations in some studies. Erythema nodosum (EN), which is one adverse event of olaparib and is discussed in this paper, is considered to be a very rare condition. A 69-year-old female patient underwent left breast conservative surgery with axillary lymph node dissection for left invasive ductal breast cancer (stage IIB). Her family history included a sister who developed ovarian cancer at age 63. Five years postoperatively, systemic metastases were discovered in the lung, bone, hilar, and poststernal lymph nodes. The surgically removed metastatic lung nodule was diagnosed as an estrogen receptor (ER)-positive, progesterone receptor (PgR)-negative, and human epidermal growth factor receptor 2 (HER2)-negative metastatic adenocarcinoma of breast cancer origin. And germline mutations of BRCA1/ 2 were assessed using BRACAnalysis CDx ® (Myriad Genetics, Salt Lake City, UT, USA), and BRCA2 1241 delC was identified as a deleterious mutation. Oral administration of olaparib was started. On day 4 of this treatment, numerous erythematous plaques characterized by intense tenderness and infiltration appeared on the extensor surfaces of the bilateral lower legs. On the basis of the clinical findings, the lesions were diagnosed as EN. Oral prednisolone was started at the same time as olaparib discontinuation, and the EN lesions disappeared in one week. EN is an inflammatory lesion characterized by tender subcutaneous induration with a flushed surface, predominantly on the bilateral lower legs. EN occurring after olaparib administration is considered to be very rare. This article describes such a case and reviews the relevant literature.

show abstract

“…Letrozole, an AI, has been used for 20 years without reported association with vitiligo, 5 although subacute cutaneous lupus erythematous, rheumatoid arthritis, and altered markers of innate, adaptive, and NK-cell-related immunity are described following AIs. 6 A modulating effect of letrozole in VLD cannot be excluded in our cases, but a primary given their well-established usage without described association with vitiligo.…”

Section: Cdk4/6 Inhibitors Drug Adverse Reaction Ribociclib Vitiligomentioning

confidence: 99%

Drug induced vitiligo‐like depigmentation from a CDK 4/6 inhibitor

Chan

Yazdabadi

et al. 2021

Asia-Pac J Clncl Oncology

View full text Add to dashboard Cite

Ribociclib is an inhibitor of cyclin-dependent kinases 4 and 6 (CDK 4/6) that is used in combination with an aromatase inhibitor in the first-line setting for advanced or metastatic hormone receptor positive and human epidermal growth factor receptor 2 (HER2)-negative breast cancer. We report two cases of drug-induced vitiligo-like depigmentation (DI-VLD) associated with ribociclib. The awareness of this side effect is important given the increasing use of this drug and others with a similar mechanism of action.

show abstract

Anastrozole-Induced Dermatitis: Report of a Woman with an Anastrozole-Associated Dermatosis and a Review of Aromatase Inhibitor-Related Cutaneous Adverse Events

Cited by 11 publications

References 20 publications

Erythema Nodosum: A Practical Approach and Diagnostic Algorithm

Erythema Nodosum: A Practical Approach and Diagnostic Algorithm

Development of Erythema Nodosum After Olaparib Treatment in a Patient With Recurrent Breast Cancer and BRCA2 Mutation: A Case Report

Drug induced vitiligo‐like depigmentation from a CDK 4/6 inhibitor

Contact Info

Product

Resources

About